<DOC>
	<DOC>NCT01715246</DOC>
	<brief_summary>The primary objective of this clinical study is to show that infants fed a standard starter infant formula with 2 Human Milk Oligosaccharides (HMOs) have a growth in line with infants fed a standard starter infant formula without HMOs.</brief_summary>
	<brief_title>Clinical Safety of a New Infant Starter Formula Containing 2 Human Milk Oligosaccharides (HMOs)</brief_title>
	<detailed_description />
	<criteria>Healthy babies Full term babies (37 weeks ≤ gestation ≤ 42 weeks) birth weight between 2500 g 4500g Having obtained the baby's legal representative's informed consent. FF groups: babies aged between birth and 14 days, exclusively formulafed at time of enrollment, whose mother independently elected, before enrollment, not to breastfeed • BF group: babies aged 3 months (+/ 5 days), exclusively breastfed since birth. Congenital illness or malformation that may affect growth Significant prenatal and/or serious postnatal disease before enrollment (by medical decision) Minor parent(s) Newborn whose parents / caregivers cannot be expected to comply with study procedures Currently participating or having participated in another clinical trial since birth, except for BF group, where vaccines studies are allowed.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>healthy babbies</keyword>
	<keyword>infant formula</keyword>
	<keyword>growth</keyword>
	<keyword>HMO</keyword>
</DOC>